Ubs Group Ag Aprea Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

Shares

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 08, 2023	BUY	$0.32 - $15.2 $6,335 - $300,914	19,797 Added 333.17%	25,739 $8,000
Q3 2022 Nov 10, 2022	SELL	$0.71 - $13.6 $3,116 - $59,704	-4,390 Reduced 42.49%	5,942 $4,000
Q2 2022 Aug 10, 2022	BUY	$0.62 - $1.94 $3,144 - $9,839	5,072 Added 96.43%	10,332 $8,000
Q1 2022 May 16, 2022	BUY	$1.59 - $3.16 $8,244 - $16,384	5,185 Added 6913.33%	5,260 $10,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $5.58 $215 - $418	75 New	75 $0
Q3 2021 Nov 15, 2021	SELL	$3.43 - $5.63 $4,534 - $7,442	-1,322 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$4.05 - $5.5 $4,710 - $6,396	-1,163 Reduced 46.8%	1,322 $6,000
Q1 2021 May 12, 2021	BUY	$4.73 - $8.15 $8,405 - $14,482	1,777 Added 250.99%	2,485 $13,000
Q4 2020 Feb 11, 2021	BUY	$4.92 - $30.67 $3,286 - $20,487	668 Added 1670.0%	708 $3,000
Q3 2020 Nov 12, 2020	SELL	$21.66 - $38.86 $67,969 - $121,942	-3,138 Reduced 98.74%	40 $1,000
Q2 2020 Jul 31, 2020	SELL	$25.47 - $39.69 $30,538 - $47,588	-1,199 Reduced 27.39%	3,178 $123,000
Q1 2020 May 01, 2020	SELL	$31.65 - $45.3 $56,463 - $80,815	-1,784 Reduced 28.96%	4,377 $152,000
Q4 2019 Feb 14, 2020	BUY	$18.94 - $49.53 $116,689 - $305,154	6,161 New	6,161 $283,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,741
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.